IL-6 serum levels and production is related to an altered immune response in polycystic ovary syndrome girls with insulin resistance
- PMID: 21547256
- PMCID: PMC3086286
- DOI: 10.1155/2011/389317
IL-6 serum levels and production is related to an altered immune response in polycystic ovary syndrome girls with insulin resistance
Abstract
Polycystic ovarian syndrome (PCOS) is frequently characterized by obesity and metabolic diseases including hypertension, insulin resistance, and diabetes in adulthood, all leading to an increased risk of atherosclerosis. The present study aimed to evaluate serum and production of inflammatory markers in adolescent Sardinian PCOS. On the basis of HOMA findings, patients were divided into noninsulin resistant (NIR) and insulin resistant (IR), and were weight- and age-matched with healthy girls. Inflammatory cytokines (TNF-α, IL-6, Il-10, TGF-β) and lipokines (leptin, adiponectin), the reactant hs-CRP, and in vitro inflammatory lympho-monocyte response to microbial stimulus were evaluated. In healthy and PCOS subjects, leptin and hs-CRP were correlated with BMI, whereas adiponectin was significantly reduced in all PCOS groups. Although cytokines were similar in all groups, Interleukin-6 (IL-6) was significantly higher in IR PCOS. Moreover, in the latter group lipopolysaccharide-activated monocytes secreted significantly higher levels of IL-6 compared to NIR and control subjects. To conclude, IR PCOS displayed increased IL-6 serum levels and higher secretion in LPS-activated monocytes, whilst revealing no differences for other inflammatory cytokines. These results suggest that in PCOS patients an altered immune response to inflammatory stimuli is present in IR, likely contributing towards determining onset of a low grade inflammation.
Figures
Similar articles
-
Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index.Dis Markers. 2009;26(4):163-70. doi: 10.3233/DMA-2009-0627. Dis Markers. 2009. PMID: 19729797 Free PMC article.
-
The impact of body mass on inflammatory markers and insulin resistance in polycystic ovary syndrome.Gynecol Endocrinol. 2015 Mar;31(3):225-8. doi: 10.3109/09513590.2014.976546. Epub 2014 Nov 6. Gynecol Endocrinol. 2015. PMID: 25373529
-
Obesity and inflammatory biomarkers in women with polycystic ovary syndrome.Eur J Obstet Gynecol Reprod Biol. 2015 Sep;192:66-71. doi: 10.1016/j.ejogrb.2015.06.022. Epub 2015 Jul 2. Eur J Obstet Gynecol Reprod Biol. 2015. PMID: 26177495
-
Chronic Low Grade Inflammation in Pathogenesis of PCOS.Int J Mol Sci. 2021 Apr 6;22(7):3789. doi: 10.3390/ijms22073789. Int J Mol Sci. 2021. PMID: 33917519 Free PMC article. Review.
-
When IGF-1 Meets Metabolic Inflammation and Polycystic Ovary Syndrome.Int Immunopharmacol. 2024 Sep 10;138:112529. doi: 10.1016/j.intimp.2024.112529. Epub 2024 Jun 27. Int Immunopharmacol. 2024. PMID: 38941670 Review.
Cited by
-
Identification of potential diagnostic genes for atherosclerosis in women with polycystic ovary syndrome.Sci Rep. 2024 Aug 6;14(1):18215. doi: 10.1038/s41598-024-69065-4. Sci Rep. 2024. PMID: 39107365 Free PMC article.
-
Chronic inflammation in polycystic ovary syndrome: A case-control study using multiple markers.Int J Reprod Biomed. 2021 Apr 22;19(4):313-320. doi: 10.18502/ijrm.v19i4.9057. eCollection 2021 Apr. Int J Reprod Biomed. 2021. PMID: 33997590 Free PMC article.
-
The Effect of Atorvastatin (and Subsequent Metformin) on Adipose Tissue Acylation-Stimulatory-Protein Concentration and Inflammatory Biomarkers in Overweight/Obese Women With Polycystic Ovary Syndrome.Front Endocrinol (Lausanne). 2019 Jun 25;10:394. doi: 10.3389/fendo.2019.00394. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31293514 Free PMC article.
-
The Effect of Curcumin on TNF-α, IL-6 and CRP Expression in a Model of Polycystic Ovary Syndrome as an Inflammation State.J Reprod Infertil. 2017 Oct-Dec;18(4):352-360. J Reprod Infertil. 2017. PMID: 29201665 Free PMC article.
-
Identification and validation of novel genes related to immune microenvironment in polycystic ovary syndrome.Medicine (Baltimore). 2024 Oct 25;103(43):e40229. doi: 10.1097/MD.0000000000040229. Medicine (Baltimore). 2024. PMID: 39470566 Free PMC article.
References
-
- Franks S. Polycystic ovary syndrome: a changing perspective. Clinical Endocrinology. 1989;31(1):87–120. - PubMed
-
- Shroff R, Kerchner A, Maifeld M, Van Beek EJR, Jagasia D, Dokras A. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. Journal of Clinical Endocrinology and Metabolism. 2007;92(12):4609–4614. - PubMed
-
- Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20(11):2414–2421. - PubMed
-
- Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism. 2003;88(6):2562–2568. - PubMed
-
- Orio Jr. F, Palomba S, Spinelli L, et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. Journal of Clinical Endocrinology and Metabolism. 2004;89(8):3696–3701. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous